Top

Published in:

01-06-2003 | Viewpoint

p27^KIP1phosphorylation by PKB/Akt leads to poor breast cancer prognosis

Author: Robert B Clarke

Published in: Breast Cancer Research | Issue 3/2003

Excerpt

Three papers published concurrently in the October issue of Nature Medicine have demonstrated new links between mitogenic cytokine signalling and the cell cycle inhibitor p27^KIP1, and have elucidated how this link may contribute to breast cancer patient prognosis [1‐3]. …

Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002, 8: 1153-1160. 10.1038/nm761. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr596.asp#liang CrossRefPubMed

Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL: PKB/Akt mediates cell-cycle progression by phosphorylation of p27^Kip1 at threonine 157 and modulation of its cellular localization. Nat Med. 2002, 8: 1145-1152. 10.1038/nm759. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr596.asp#shin CrossRefPubMed

Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27^Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002, 8: 1136-1144. 10.1038/nm762. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr596.asp#viglietto CrossRefPubMed

Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13: 1501-1512.CrossRefPubMed

Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol. 1994, 14: 3683-3694.CrossRefPubMedPubMedCentral

Slingerland J, Pagano M: Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000, 183: 10-17. 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.3.CO;2-9.CrossRefPubMed

Sun H, Lesche R, Li DM, Liliental J, Zhang JH, Gao J, Gavrilova N, Mueller B, Liu X, Wu H: PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1999, 96: 6199-6204. 10.1073/pnas.96.11.6199.CrossRefPubMedPubMedCentral

Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A. 2001, 98: 10983-10985. 10.1073/pnas.211430998.CrossRefPubMedPubMedCentral

Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC: Cytoplasmic localization of p21^Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001, 3: 245-252. 10.1038/35060032.CrossRefPubMed

This article is based on papers highlighted by Faculty of 1000 http://www.facultyof1000.com/start.asp, a web-based literature awareness service. Faculty of 1000 evaluations available for articles cited in this report may be viewed at: http://breast-cancer-research.com/reports/bcr596.asp

Title: p27KIP1phosphorylation by PKB/Akt leads to poor breast cancer prognosis
Author: Robert B Clarke
Publication date: 01-06-2003
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 3/2003
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr596

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2003

Inflammatory breast cancer: Relationship between growth factor signaling and motility in aggressive cancers

Inflammatory breast cancer: Vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model

C766T low-density lipoprotein receptor-related protein 1 (LRP1) gene polymorphism and susceptibility to breast cancer

Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype

Keynote webinar | Spotlight on antibody–drug conjugates in cancer